Interleukin-20 targets renal mesangial cells and is associated with lupus nephritis

Clinical Immunology

Volumn 129, Issue 2, 2008, Pages 277-285

  Li, Hsing Hui ^a,b   Cheng, He Hsiung ^c   Sun, Kuang Hui ^d   Wei, Chi Chen ^a,e   Li, Chien Feng ^b   Chen, Wen Chung ^a   Wu, Wen Mein ^f   Chang, Ming Shi ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c CHANG BING SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

^f FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

IL 20; Lupus nephritis; Mesangial cell

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 20; INTERLEUKIN 20 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPOXEMIA; KIDNEY BIOPSY; KIDNEY CELL; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MESANGIUM CELL; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CELLS, CULTURED; CHEMOKINES; CHILD; CYTOKINES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; INTERLEUKINS; LUPUS NEPHRITIS; MALE; MESANGIAL CELLS; MICE; MICE, INBRED DBA; MICE, INBRED NZB; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE II; REACTIVE OXYGEN SPECIES; SPLEEN;

EID: 53749095820     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.07.006     Document Type: Article

References (28)

1. A.N. Malaviya, R.R. Singh, A. Kumar, A. De, A. Kumar, S. Aradhye, Systemic lupus erythematosus in northern India: a review of 329 cases, J. Assoc. Physicians India 36 (1988) 476-480, 484.
2. Oates J.C., and Gilkeson G.S. Mediators of injury in lupus nephritis. Curr. Opin. Rheumatol. 14 (2002) 498-503
3. Ahsan H., Ali A., and Ali R. Oxygen free radicals and systemic autoimmunity. Clin. Exp. Immunol. 131 (2003) 398-404
4. Oates J.C., and Gilkeson G.S. The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus. Clin. Immunol. 121 (2006) 243-250
5. Belmont H.M., Levartovsky D., Goel A., Amin A., Giorno R., Rediske J., Skovron M.L., and Abramson S.B. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis. Rheum. 40 (1997) 1810-1816
6. Theofilopoulos A.N., and Dixon F.J. Murine models of systemic lupus erythematosus. Adv. Immunol. 37 (1985) 269-390
7. Wakeland E.K., Wandstrat A.E., Liu K., and Morel L. Genetic dissection of systemic lupus erythematosus. Curr. Opin. Immunol. 11 (1999) 701-707
8. Moore K.W., de Waal Malefyt R., Coffman R.L., and O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19 (2001) 683-765
9. Fouqueray B., Boutard V., Philippe C., Kornreich A., Marchant A., Perez J., Goldman M., and Baud L. Mesangial cell-derived interleukin-10 modulates mesangial cell response to lipopolysaccharide. Am. J. Pathol. 147 (1995) 176-182
10. Chadban S.J., Tesch G.H., Foti R., Atkins R.C., and Nikolic-Paterson D.J. Interleukin-10 is a mesangial cell growth factor in vitro and in vivo. Lab. Invest. 76 (1997) 619-627
11. Houssiau F.A., Lefebvre C., Vanden Berghe M., Lambert M., Devogelaer J.P., and Renauld J.C. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 4 (1995) 393-395
12. Ishida H., Muchamuel T., Sakaguchi S., Andrade S., Menon S., and Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med. 179 (1994) 305-310
13. Blumberg H., Conklin D., Xu W.F., Grossmann A., Brender T., Carollo S., Eagan M., Foster D., Haldeman B.A., Hammond A., Haugen H., Jelinek L., Kelly J.D., Madden K., Maurer M.F., Parrish-Novak J., Prunkard D., Sexson S., Sprecher C., Waggie K., West J., Whitmore T.E., Yao L., Kuechle M.K., Dale B.A., and Chandrasekher Y.A. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 104 (2001) 9-19
14. Pestka S., Krause C.D., Sarkar D., Walter M.R., Shi Y., and Fisher P.B. Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol. 22 (2004) 929-979
15. Wolk K., Kunz S., Asadullah K., and Sabat R. Cutting edge: immune cells as sources and targets of the IL-10 family members?. J. Immunol. 168 (2002) 5397-5402
16. Perez de Lema G., Maier H., Nieto E., Vielhauer V., Luckow B., Mampaso F., and Schlondorff D. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J. Am. Soc. Nephrol. 12 (2001) 1369-1382
17. Ka S.M., Cheng C.W., Shui H.A., Wu W.M., Chang D.M., Lin Y.C., and Chen A. Mesangial cells of lupus-prone mice are sensitive to chemokine production. Arthritis Res. Ther. 9 (2007) R67
18. Wei C.C., Chen W.Y., Wang Y.C., Chen P.J., Lee J.Y., Wong T.W., Chen W.C., Wu J.C., Chen G.Y., Chang M.S., and Lin Y.C. Detection of IL-20 and its receptors on psoriatic skin. Clin. Immunol. 117 (2005) 65-72
19. Abramson S.B., Dobro J., Eberle M.A., Benton M., Reibman J., Epstein H., Rapoport D.M., Belmont H.M., and Goldring R.M. Acute reversible hypoxemia in systemic lupus erythematosus. Ann. Intern. Med. 114 (1991) 941-947
20. Martinez-Taboada V.M., Blanco R., Armona J., Fernandez-Sueiro J.L., and Rodriguez-Valverde V. Acute reversible hypoxemia in systemic lupus erythematosus: a new syndrome or an index of disease activity?. Lupus 4 (1995) 259-262
21. Chen W.Y., Cheng B.C., Jiang M.J., Hsieh M.Y., and Chang M.S. IL-20 is expressed in atherosclerosis plaques and promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 2090-2095
22. Yuan Y., Hilliard G., Ferguson T., and Millhorn D.E. Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J. Biol. Chem. 278 (2003) 15911-15916
23. Cooke M.S., Mistry N., Wood C., Herbert K.E., and Lunec J. Immunogenicity of DNA damaged by reactive oxygen species-implications for anti-DNA antibodies in lupus. Free Radic. Biol. Med. 22 (1997) 151-159
24. Hsieh M.Y., Chen W.Y., Jiang M.J., Cheng B.C., Huang T.Y., and Chang M.S. Interleukin-20 promotes angiogenesis in a direct and indirect manner. Genes Immun. 7 (2006) 234-242
25. Noris M., Bernasconi S., Casiraghi F., Sozzani S., Gotti E., Remuzzi G., and Mantovani A. Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab. Invest. 73 (1995) 804-809
26. Muraguchi A., Hirano T., Tang B., Matsuda T., Horii Y., Nakajima K., and Kishimoto T. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J. Exp. Med. 167 (1988) 332-344
27. Malide D., Russo P., and Bendayan M. Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum. Pathol. 26 (1995) 558-564
28. Lui S.L., Tsang R., Wong D., Chan K.W., Chan T.M., Fung P.C., and Lai K.N. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice. Lupus 11 (2002) 411-418